Table 2.
Demographics and baseline clinical characteristics of the RA patients
| Baseline characteristics | Overall n = 625 | Responder n = 466 | Non-responder n = 159 | p-value |
|---|---|---|---|---|
| Sex (male, %) | 103 (16.5) | 80 (17.2) | 23 (14.5) | 0.503 |
| Age at baseline (years) | 54.04 (12.44) | 54.13 (12.40) | 53.78 (12.61) | 0.757 |
| Disease duration (years) | 6.78 (7.19) | 6.66 (7.20) | 7.14 (7.17) | 0.464 |
| Height (cm) | 159.41 (7.01) | 159.50 (7.08) | 159.16 (6.81) | 0.606 |
| Weight (kg) | 57.30 (9.72) | 57.08 (9.45) | 57.93 (10.47) | 0.341 |
| SJC | 6.71 (5.18) | 7.00 (5.10) | 5.87 (5.36) | 0.017 |
| TJC | 8.50 (5.98) | 8.78 (5.98) | 7.68 (5.93) | 0.045 |
| PtGA | 7.24 (1.78) | 7.47 (1.69) | 6.55 (1.87) | <0.001 |
| PhGA | 6.56 (1.75) | 6.69 (1.72) | 6.18 (1.78) | 0.001 |
| RAPID3 | 15.54 (5.68) | 16.10 (5.70) | 13.89 (5.30) | <0.001 |
| ESR (mm/h) | 46.63 (25.66) | 46.38 (25.98) | 47.36 (24.77) | 0.678 |
| CRP (mg/dL) | 2.34 (3.16) | 2.40 (3.00) | 2.16 (3.59) | 0.405 |
| HTN (%) | 167 (26.7) | 126 (27.0) | 41 (25.8) | 0.838 |
| DM (%) | 61 (9.8) | 36 (7.7) | 25 (15.7) | 0.005 |
| CKD (%) | 5 (0.8) | 3 (0.6) | 2 (1.3) | 0.814 |
| Rheumatoid factor positive (%) | 551 (88.2) | 410 (88.0) | 141 (88.7) | 0.926 |
| Anti-CCP positive (%) | 494 (79.0) | 373 (80.0) | 121 (76.1) | 0.346 |
| Methotrexate (%) | 531 (85.0) | 400 (85.8) | 131 (82.4) | 0.357 |
| Hydroxychloroquine (%) | 175 (28.0) | 136 (29.2) | 39 (24.5) | 0.304 |
| Sulfasalazine (%) | 85 (13.6) | 67 (14.4) | 18 (11.3) | 0.403 |
| Leflunomide (%) | 179 (28.6) | 127 (27.3) | 52 (32.7) | 0.226 |
| Abatacept (%) | 68 (10.9) | 49 (10.5) | 19 (11.9) | 0.723 |
| Adalimumab (%) | 168 (26.9) | 121 (26.0) | 47 (29.6) | 0.436 |
| Etanercept (%) | 94 (15.0) | 64 (13.7) | 30 (18.9) | 0.151 |
| Golimumab (%) | 26 (4.2) | 18 (3.9) | 8 (5.0) | 0.684 |
| Infliximab (%) | 64 (10.2) | 40 (8.6) | 24 (15.1) | 0.029 |
| Tocilizumab (%) | 194 (31.0) | 165 (35.4) | 29 (18.2) | <0.001 |
| Tofacitinib (%) | 11 (1.8) | 9 (1.9) | 2 (1.3) | 0.835 |
Data are shown in mean (standard deviation) if not otherwise specified
SJC swollen joint count, TJC tender joint count, PtGA patient global assessment of disease activity, PhGA physician global assessment of disease activity, RAPID3 routine assessment of patient index data 3, ESR erythrocyte sedimentation rate, CRP C-reactive protein, HTN hypertension, DM diabetes mellitus, CKD chronic kidney disease, anti-CCP anti-citrullinated protein